Drugs that target pro-MDS proteins, which facilitate the differentiation of myeloid precursors into MDS and Treg recruitments (such as focal adhesion kinase (FAK), Bruton tyrosine kinase (BTK), and CXCR4) [146,147,148,149,150,151,152,153,154,155], are currently under investigation with some promising preliminary results. This evidence concerns the gene BTK and myelodysplastic syndrome.